Search the Newsreel

Nektar Therapeutics (NKTR) Could Be 52% Undervalued After Q2 Earnings Surprise

Ikarian Capital (KZIA) discloses 575,778 Kazia Therapeutics ADSs under 4.9% cap

Pliant Therapeutics (PLRX) gains 8.9% institutional holder in ADAR1 Capital

Cyclerion Therapeutics (CYCN): ADAR1 Capital discloses 7.0% beneficial ownership

ADAR1 Capital Management, LLC and Daniel Schneeberger have reported beneficial ownership of 7.0% of Cyclerion Therapeutics, Inc. (CYCN) common stock, totaling 298,757 shares. This ownership is held by private investment funds managed by ADAR1, with both reporting persons exercising shared voting and dispositive power. …

Ikarian Capital (TENX) discloses 2.9% beneficial stake in Tenax Therapeutics common stock

Ikarian Capital, LLC and Neil Shahrestani have reported a 2.9% beneficial ownership stake in Tenax Therapeutics, Inc. (TENX) common stock, totaling 1,080,700 shares. This includes 373,100 shares acquirable within 60 days via options, based on 37,423,917 shares outstanding as of July 28, 2026. The …

Outlook Therapeutics CEO Robert Jahr acquires shares and warrants for $0

Outlook Therapeutics CEO Robert Jahr recently acquired 151,515 shares of common stock and an equal number of warrants. This transaction occurred at a combined public offering price of $0.99 per unit, amounting to $0, with each warrant allowing the purchase of one share at …

Outlook Therapeutics (OTLK) CEO purchases 151,515 shares and matching warrants

Outlook Therapeutics (OTLK) CEO Robert Charles Jahr purchased 151,515 shares of common stock and 151,515 accompanying warrants on August 14, 2026. The transaction occurred in an underwritten public offering at a combined price of $0.99 per share and warrant. The warrants are exercisable immediately …

NEKTAR THERAPEUTICS Q2 2026: Revenue $10.1M, EPS $(1.23) — 10-Q Summary

NEKTAR THERAPEUTICS reported Q2 2026 results with revenue of $10.1 million and a net loss of $40.6 million, an improvement from the $41.6 million loss in the prior year. The diluted loss per share was $(1.23). The company highlighted advancements in its pipeline, including …

Nektar Therapeutics Q2 Earnings Call Highlights

Nektar Therapeutics announced the initiation of its global Phase III ZENITH AD program for rezpegaldesleukin (REZPEG) in moderate-to-severe atopic dermatitis, with top-line data expected in mid-2028 and a potential BLA submission in 2029. The company also finalized plans for a registrational Phase III trial …

ProQR Therapeutics (PRQR) Stock Rises On Revenue Surge As Losses Ease

Neumora Therapeutics (NASDAQ:NMRA) Announces Earnings Results, Beats Estimates By $0.01 EPS

Neumora Therapeutics (NASDAQ:NMRA) reported a Q2 loss of $0.23 per share, exceeding analyst expectations by $0.01. Despite beating estimates, the stock fell by $0.13 to $1.60 and remains significantly below its 12-month high. Institutional investors own 47.65% of the company, and analysts have a …

PERCEPTIVE ADVISORS LLC Expands Relay Therapeutics Inc (RLAY) Stake -- Shares Look 421% Overvalued on GF Value

Perceptive Advisors LLC significantly increased its stake in Relay Therapeutics Inc (RLAY) by purchasing 13.67 million shares, bringing their total ownership to 6.40%. Despite this strong conviction from a specialized healthcare investment firm, GuruFocus identifies RLAY shares as "Significantly Overvalued" by 421% based on …

Novo Holdings A/S (COAG) discloses 9.0% beneficial stake in Hemab Therapeutics

Novo Holdings A/S, an investment firm owned by the Novo Nordisk Foundation, has disclosed a 9.0% beneficial stake in Hemab Therapeutics Holdings, Inc., equating to 4,180,550 shares of common stock. Novo Holdings A/S holds sole voting and dispositive power over these shares. The filing …

Outlook Therapeutics, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:OTLK) 2026-08-14

Rein Therapeutics (NASDAQ:RNTX) Announces Earnings Results

ProQR Therapeutics (NASDAQ:PRQR) Announces Earnings Results

Galectin Therapeutics (NASDAQ:GALT) Issues Quarterly Earnings Results

Pasithea Therapeutics Corp. Q2 2026: Net loss $(5.27M), EPS $(0.16) — 10-Q Summary

Pasithea Therapeutics Corp. reported a Q2 2026 net loss of $(5.27M) and diluted EPS of $(0.16), marking a wider loss compared to the previous year. The company is advancing its PAS-004 clinical development programs, with a significant increase in R&D expenses. Pasithea has refocused …

Stockholder Alert: Robbins LLP Informs Investors of the Aardvark Therapeutics, Inc. (UWM) Class Action

Robbins LLP has filed a class action lawsuit against Aardvark Therapeutics, Inc. (NASDAQ: AARD) on behalf of investors who purchased shares during its February 13, 2025 IPO or between February 13, 2025 and May 14, 2026. The lawsuit alleges that Aardvark misled investors regarding …

CCORF Initiates Kazia Therapeutics(KZIA.US) With Buy Rating, Announces Target Price $29

CCORF has initiated coverage on Kazia Therapeutics (KZIA.US) with a Buy rating and set a price target of $29. This new rating suggests a positive outlook for the company's stock from CCORF.

Abeona Therapeutics (ABEO) Stock Faces Early Launch Strain Despite Revenue Traction

Stifel Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $6

Stifel has reiterated its Buy rating on Compass Therapeutics (CMPX.US) and maintained its target price of $6. This indicates the firm's continued confidence in the company's prospects.

Fate Therapeutics (FATE) Stock Drifts Higher Despite Persistent Cash Burn

Fate Therapeutics (FATE) stock saw a modest increase despite reporting significant losses in Q2 2026, with a net loss of US$30 million. While the company's revenue slightly increased year-over-year and losses narrowed, funding risk remains due to its substantial cash burn. Bullish sentiment is …

Can Keros Therapeutics (KROS)’s $20M Takeda Pharmaceutical Company Limited (TAK) Milestone Unlock a Billion-Dollar Opportunity?

On July 30, Keros Therapeutics, Inc. (NASDAQ:KROS) triggered a $20 million development milestone payment from its global partner Takeda Pharmaceutical Company Limited (NYSE:TAK). The payout followed the first patient dosed in the Phase 3 ELRiSE MDS clinical trial, evaluating elritercept against epoetin alfa for …

Tapestry (TPR), Why Is Its Latest Update Drawing Attention?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Tapestry (TPR) just reported fourth quarter and full year results that included higher sales, a swing to profit, and increased dividends, yet the stock …

Kaplan Fox Deadline Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Have Until September 28, 2026 to Seek a Lead Plaintiff Role

Kaplan Fox & Kilsheimer LLP has announced a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) for investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor made undisclosed changes to its statistical analysis plan for …

Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) SVP Sells 10,000 Shares of Stock

COYA|Coya Therapeutics Inc|Price:4.790|Chg%:+0.120

ADC Therapeutics (ADCT) Stock Faces LOTIS 5 Doubts Despite Narrower Loss

BioXcel Therapeutics (BTAI) files Form 3 for new director Susan E. Atkins

BioXcel Therapeutics, Inc. (BTAI) has filed a Form 3 to report the initial beneficial ownership for its new director, Susan E. Atkins. This filing indicates her position as a director but does not list any equity transactions or current holdings. The document also notes …

BioXcel Therapeutics (BTAI) director receives option grant for 17,000 shares

BioXcel Therapeutics director Susan E. Atkins was granted stock options for 17,000 shares of common stock on August 12, 2026, with an exercise price of $1.06 per share and an expiration date of August 12, 2036. The options will vest over three years, with …

Tapestry (TPR) Stock Can Profit Strength Outrun Kate Spade Drag?

Vivos Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript

Vivos Therapeutics reported a 35% increase in second-quarter revenue to $5.2 million, driven by service revenue from sleep testing and Vivos treatment, leading to an improved gross margin of 57%. The company is pursuing several growth initiatives, including remote patient monitoring for CPAP patients, …

What Could Push TPR Stock Higher From Here?

Photo by Pexels on Pixabay At $128.39, Tapestry (TPR) looks set up for roughly 22% upside over the next three years under a conservative scenario. Not a big number, and most of what the business is doing is already in the price. The question …

H.C. Wainwright reiterates Buy on 4D Molecular stock, $36 target By Investing.com

H.C. Wainwright has reiterated a Buy rating on 4D Molecular Therapeutics (NASDAQ:FDMT) with a $36.00 price target, citing positive two-year data from the Phase 2b PRISM trial for its 4D-150 gene therapy. The company has also completed enrollment for its pivotal Phase 3 4FRONT-2 …

Vistagen Therapeutics (VTGN): OrbiMed reports 0.0% beneficial ownership in latest 13G/A